Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation

Affiliation

• ¹ Brian C. Shaffer, MD, MS, Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Mahasweta Gooptu, MD, Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA; Todd DeFor, MS, Stephen R. Spellman, MBS, and Heather E. Stefanski, MD, PhD, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN; Bronwen E. Shaw, MD, PhD, CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Jeffery J. Auletta, MD, and Steven M. Devine, MD, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN; Antonio M. Jimenez, MD, MSc, Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL, and Monzr M. Al Malki, MD, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.